Five new deaths were reported on Wednesday alone, but authorities
had no plans to suspend the vaccination programme, unless
investigations, including post mortems, revealed a link, which
preliminary findings had not.
"We have reviewed whether it is appropriate to continue the
vaccination or better to suspend and wait for the results," health
official Kim Joong-gon told a briefing.
"We came to the conclusion that the deaths had no direct relations
with the vaccination given the limited data we have now and without
detailed post mortem reports."
Kim said a preliminary investigation into six victims revealed five
had underlying conditions.
Health officials also said no toxic substances had been found in the
same vaccine administered to other people.

Coming just weeks after the roll out of the national vaccine
programme was temporarily suspended over safety worries, the deaths,
which include a 17-year-old boy and a man in his 70s, have dominated
news headlines in South Korea.
With winter approaching, the country is planning to inoculate 30
million people in a bid to prevent the health system being
overloaded by patients with flu and COVID-19 exposure.
However, the start of a free jab programme for around 19 million
eligible people was suspended for three weeks after it was
discovered that some 5 million doses, which need to be refrigerated,
had been exposed to room temperature while being transported to a
medical facility.
[to top of second column] |

Officials said 8.36 million people have been given the free flu vaccine since
inoculations resumed on Oct. 13.
Adverse reactions - which included fever, diarrhoea and allergies, according to
Korea Disease Control and Prevention Agency (KDCA) chief Jeong Eun-kyeong - were
reported in 430 people who received the jabs.
The number is higher than 132 and 177 cases of adverse reactions reported in
2018 and 2019 respectively.
Since 2009, some 25 people who received a seasonal flu vaccination have died,
but cause-and-effect has not been established, Jeong said.
Suppliers of the vaccines for this year's programme include LG Chem Ltd
<051910.KS> and Boryung Biopharma, a unit of Boryung Pharm Co. Ltd. <003850.KS>.
A Boryung official said it has no immediate comment. LG Chem said it would
follow government advice.
(Reporting by Sangmi Cha; Editing by Miyoung Kim and Jane Wardell & Simon
Cameron-Moore)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
 |